Financial reports
10-Q
2024 Q2
Quarterly report
9 Feb 24
ARS
2023 FY
Annual report to shareholders
16 Nov 23
10-Q
2024 Q1
Quarterly report
8 Nov 23
10-K
2023 FY
Annual report
23 Aug 23
10-Q
2023 Q3
Quarterly report
11 May 23
10-Q
2023 Q2
Quarterly report
14 Feb 23
10-Q
2023 Q1
Quarterly report
10 Nov 22
10-K
2022 FY
Annual report
22 Sep 22
Current reports
8-K
Results of Operations and Financial Condition
18 Apr 24
8-K
Regulation FD Disclosure
12 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
8-K
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
12 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
29 Feb 24
8-K
Other Events
20 Feb 24
8-K
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
9 Feb 24
8-K
Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds
7 Feb 24
8-K
Results of Operations and Financial Condition
2 Feb 24
Registration and prospectus
424B3
Prospectus supplement
28 Mar 24
D
$10.10 mm in equity / options, sold $10.10 mm, 8 investors
22 Mar 24
S-3
Shelf registration
18 Mar 24
424B3
Prospectus supplement
18 Mar 24
S-3
Shelf registration
4 Mar 24
S-8
Registration of securities for employees
12 Jan 24
424B4
Prospectus supplement with pricing info
3 Oct 23
S-1/A
IPO registration (amended)
28 Sep 23
S-1/A
IPO registration (amended)
22 Sep 23
S-1/A
IPO registration (amended)
11 Sep 23
Proxies
DEF 14A
Definitive proxy
17 Nov 23
PRE 14A
Preliminary proxy
7 Nov 23
DEF 14A
Definitive proxy
20 Oct 23
PRE 14A
Preliminary proxy
10 Oct 23
DEF 14A
Definitive proxy
10 Apr 23
PRE 14A
Preliminary proxy
29 Mar 23
DEF 14A
Definitive proxy
4 Jan 23
PRE 14A
Preliminary proxy
23 Dec 22
DEFA14A
Additional proxy soliciting materials
14 Jul 22
DEFA14A
Additional proxy soliciting materials
27 Jun 22
Other
EFFECT
Notice of effectiveness
28 Mar 24
EFFECT
Notice of effectiveness
18 Mar 24
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
29 Sep 23
CORRESP
Correspondence with SEC
29 Sep 23
CORRESP
Correspondence with SEC
5 Sep 23
UPLOAD
Letter from SEC
8 Aug 23
CORRESP
Correspondence with SEC
27 Jul 23
UPLOAD
Letter from SEC
19 Jul 23
EFFECT
Notice of effectiveness
28 Jun 23
Ownership
4
Spiro Kevin Sakiris
21 Mar 24
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
Bigger Capital, LLC
5 Feb 24
SC 13G
Lind Global Fund II LP
20 Oct 23
SC 13G
Lind Global Fund II LP
10 Oct 23
4/A
Spiro Kevin Sakiris
10 Oct 23
4
CHRISTOPHER TOWERS
6 Oct 23
4
Spiro Kevin Sakiris
6 Oct 23
SC 13G
BIGGER CAPITAL FUND L P
4 Oct 23